Gefitinib + Docetaxel
ApprovedTerminated 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Carcinoma, Non-Small-Cell Lung
Conditions
Carcinoma, Non-Small-Cell Lung
Trial Timeline
Oct 1, 2007 → Aug 1, 2009
NCT ID
NCT00536107About Gefitinib + Docetaxel
Gefitinib + Docetaxel is a approved stage product being developed by AstraZeneca for Carcinoma, Non-Small-Cell Lung. The current trial status is terminated. This product is registered under clinical trial identifier NCT00536107. Target conditions include Carcinoma, Non-Small-Cell Lung.
What happened to similar drugs?
20 of 20 similar drugs in Carcinoma, Non-Small-Cell Lung were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00536107 | Approved | Terminated |
| NCT00478049 | Phase 3 | Completed |
| NCT00076388 | Phase 3 | Completed |
| NCT00319618 | Phase 2 | Completed |
| NCT00247481 | Phase 2 | Completed |
Competing Products
20 competing products in Carcinoma, Non-Small-Cell Lung